RT Journal Article
SR Electronic
T1 Influence of age on the effectiveness and duration of protection in Vaxzevria and CoronaVac vaccines
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.21.21261501
DO 10.1101/2021.08.21.21261501
A1 Thiago Cerqueira-Silva
A1 Vinicius de Araújo Oliveira
A1 Julia Pescarini
A1 Juracy Bertoldo Júnior
A1 Tales Mota Machado
A1 Renzo Flores-Ortiz
A1 Gerson Penna
A1 Maria Yury Ichihara
A1 Jacson Venâncio de Barros
A1 Viviane S. Boaventura
A1 Mauricio L. Barreto
A1 Guilherme Loureiro Werneck
A1 Manoel Barral-Netto
YR 2021
UL http://medrxiv.org/content/early/2021/08/27/2021.08.21.21261501.abstract
AB Background High rates of virus transmission and the presence of variants of concern can affect vaccine effectiveness (VE). Both conditions occur in low-income countries, which primarily use viral vector or inactivated virus vaccine technologies. Such countries conducted few VE analyses, and most lack the power to evaluate effectiveness in subgroups.Methods The present retrospective cohort study evaluated the effectiveness of Vaxzevria and CoronaVac vaccines for COVID-19-related infection in 75,919,840 Brazilian vaccinees from January 18 to July 24, 2021.Study outcomes included documented infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19–related hospitalization, ICU admission, and death. We estimated VE using Cox regression adjusted for individual demographic characteristics.Results Vaccination with Vaxzevria or CoronaVac was effective against SARS-CoV-2 infection and highly effective against hospitalization, ICU admission, and death in individuals up to 79 years. From 80-89 years of age, Vaxzevria led to 89.9%(95CI:87.7-91.7) VE against death versus 67.2%(95CI:63.6-70.5) for CoronaVac. Above 90 years, 65.4%(95CI:46.1-77.8) protection was conferred to Vaxzevria-vaccinated individuals versus 33.6%(95CI:21.9-43.5) in CoronaVac-vaccinated individuals. Furthermore, the post-vaccination daily incidence rate shows a stepwise increase from younger to elder decades of life.Conclusions Vaxzevria demonstrated overall effectiveness against severe COVID-19 up to 89 years and CoronaVac up to 79 years of age. There is a stepwise effectiveness reduction for both vaccines for each decade of life. Our results suggest that individuals aged 80 years or older may benefit from an expedited booster dose. Ongoing evaluations, including any additional vaccines authorized, are crucial to monitoring long-term vaccine effectiveness.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFUNDING This study was partially supported by a donation from the "Fazer o bem faz bem"-JBS program. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Brazilian National Commission in Research Ethics approved the research protocol (CONEP approval number 4.921.308). The study was considered exempt from informed consent; no human health risks were identified. All work presented here used unidentified secondary data in accordance with the Brazilian Personal Data Protection General Law (LGPD). Data was manipulated in a secure computing environment, ensuring protection against data leakage and records reidentification.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe used third-party data, provided by the Brazilian Ministry of Health. Any request for access to the data shall be directed to DATASUS - Ministry of Health Brazil: https://datasus.saude.gov.br/ https://datasus.saude.gov.br/